Latest EU Pharma Reform Proposals Risk Stifling Innovation And Competitiveness

EU policymakers have the chance to adopt legislation that establishes a strong and predictable framework of incentives for R&D into new medicines, particularly those that require riskier investments, says CSL Behring’s Lutz Bonacker.

Cardboard box with question mark - Concept of mystery box
Stakeholders have many questions about the EU pharma reform package • Source: Shutterstock

The European Parliament’s amendments to the EU pharmaceutical reform proposals, particularly on regulatory data protection (RDP) and orphan drug exclusivity periods, could impair companies’ ability to plan their R&D investments in Europe, according to Lutz Bonacker, general manager of commercial operations of CSL Behring.

“As currently proposed, I think there's a risk that Europe will become less attractive and less competitive in the years...

More from Europe

More from Geography